Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts


Article Index

If You Own Just One Pharma Stock, Make It This

pharma stock

As I've said before, buying a drugmaker with true billion-dollar "blockbuster" potential is like grabbing a license to print money.

Of course, it's always at least possible to grab these shares on their way up, but that's a little like fixing the barn door after the horses have bolted.

For the biggest possible pharma profits, investors have to look ahead into the firm's "pipeline," its arsenal of yet-to-be-released drugs that's critical to keeping a drug company competitive in the long term.

Today, I've got the perfect "Buy" recommendation for a company that's doing just that...

How to Grab 100% of’s Profit Potential for 3% of the Price


When made its Nasdaq debut on May 16, 1997, regular investors lucky enough to get in on it could've snagged shares for a split- and dividend-adjusted price of less than $1.75 each. 

Those early investors have realized eye-watering gains of more than 52,110%; shares of the e-commerce juggernaut are trading at more than $900. And it's still a good growth play.

But... Our Technical Trading Specialist, D.R. Barton, has an even better stock to recommend, with at least as much upside. It's a huge e-commerce player that's not only holding its own against "Team Bezos," but making some serious inroads against the standard by which all other e-commerce stocks are judged.

The best part is, thanks to a minor miss in its earnings report, it's on sale... until Wall Street realizes what happened.

And, as D.R.'s Stealth Profits Trader readers will tell you, a great company on a pullback means monster profits ahead.

So he appeared on CNBC World to explain the profitable setup and tell everyone why this is his favorite stock of the week...

All of Our North Korea Predictions Are Coming to Fruition

North Korea

Bill said before that sometime between now and the end of Trump's term, the White House is going to have to grapple with a huge - and potentially deadly - decision about North Korea and its nuclear weapons program.

But there are two companies that represent a huge opportunity as tensions ramp up...

Everything We’ve Said About North Korea Is Coming True

North Korea

Bill said before that sometime between now and the end of Trump's term, the White House is going to have to grapple with a huge - and potentially deadly - decision about North Korea and its nuclear weapons program.

But there are two companies that represent a huge opportunity as tensions ramp up...

What Really Went on in Mar-a-Lago… and How to Profit from It


My friend Jack couldn't fathom how last week's historic meeting between Chinese President Xi Jinping and U.S. President Donald J. Trump didn't end in a diplomatic donnybrook.

"...but Trump hates China?!"

Like many investors who expected the gloves to come off, he's wondering what gives - and what this means for his money.

I've got a few answers, and I think you're going to be very excited by what I have to say about where to position your money next, especially if you "missed" Amazon.

Here's what you need to know...

Top Stocks to Watch Today: UL, BBBY, YUMC

stocks to watch

The top three stocks to watch today are UL, BBBY, and YUMC.

President Trump meets Chinese President Xi today with discussions about trade and North Korea taking priority.

Here's what you need to know this morning...

This Company Proves the "Ten-Bagger Stock" Is No Myth


Back in August 2011, for the very first edition of Private Briefing, I recommended a Belgian biotech firm that I said was "like buying an independent drug development lab" for less than nine bucks a share - $8.60, in fact.

I zeroed in on the company's collaborative partnerships on a whole slew of drug development programs.

Now, I love to see this in a biotech stock, because it means that some of the usual risks of owning a small, clinical-stage company - running out of money, or the risk of one trial failure wiping out the firm - were minimized.

That arrangement was critical in the massive, almost tenfold gains that followed. (And, as you'll see, it's going to be just as important in the bigger gains I see down the road for the folks who bought this company.)

I've recommended these shares for my subscribers more than a dozen times since, each time before a fresh bumper crop of profits. This company has given more than 931% in peak gains for Private Briefing subscribers, and a market-crushing 26% since I first shared it with Money Morning Members in September 2016.

There's a very specific reason I see these gains getting even bigger for everyone in the future...

Here's a Pure Play in a $25 Billion "Frontier" Market

frontier market

Chemotherapy and radiation have been cancer treatments since the 1950s, and in the meantime, science has developed more than 200 drugs to fight cancer.

All these established treatments have one thing in common. They're all more or less "one size fits all" treatments, procedures, or regimens.

But out on the frontier of cancer research where, as I've said, the most exciting, promising discoveries (and biggest profits) are made, there's a treatment under development that's going to disrupt the field for the next several decades.

I'm talking about powerful "bespoke" cancer treatments for every patient, using their own bodies to boot.

Not only will this improve and save lives, but it'll crack open a market worth $25 billion by 2025.

It really is a revolutionary development.

But the "Buy" call I'm making today is still trading at "pre-revolutionary" prices...

WWE Stock Will Plunge After WrestleMania, Here's How to Profit

wwe stock

There's a strong chance shares of WWE stock will fall on Monday (April 3), and savvy investors can take advantage of this trend for a quick profit...

Sunday night is WrestleMania, the biggest event of the year for World Wrestling Entertainment, and one traders anticipate every year.

That's why we're going to show you a simple strategy to make big profits from this WWE stock trend...

How Bill Finds the Best Stocks First

best stocks

Private Briefing's Bill Patalon has shown us quite a bit about finding the best stocks at great prices.

For instance, one of the things he looks for is high levels of "insider buying" (not insider trading), which is a very potent profit catalyst for stocks. After all, insiders sell their shares for all kinds of reasons, but they buy for one reason alone: They expect the stock to go straight up.

Another method Bill uses to bullseye shares, particularly when making a prescient "early" call, is the business model. A solid business model, especially from the get-go, almost always brings in solid revenue later.

Especially potent is the old "give 'em the razor, sell 'em the blades" model of locking in a juicy revenue stream.

It was perfected by King Camp Gillette in the early 20th century, and you know how it works: The durable razors can be had for cheap... but the disposable blades you need to stick on the business end are often three or four times more expensive, and most people need a steady supply.

That's expensive if you're a customer, but it ought to make investors' eyes light up.

It's an old, profitable technique, but it's actually becoming more widespread - and more profitable - as time goes on...

How to Profit from the U.S.-U.K. Marijuana “Research Gap”

2017 Legal Marijuana Forecast

Legal marijuana flat-Earthers, like U.S. Attorney General Jeff Sessions, have tried many methods to discredit breakthroughs in medical cannabis, which is now legal in 28 states.

This is of course all despite thousands of documented positive cases where marijuana helped sufferers cope with afflictions like cancer, multiple sclerosis, and epilepsy.

But, as you'll see, these efforts at discrediting cannabis stop at the U.S. border. Several other countries, especially the United Kingdom, have created a far more favorable climate for cannabis research and innovation.

Don't get me wrong - I'm extremely bullish on the future state of American public cannabis research and its potential to bring new products to a huge market, largely because the momentum for marijuana is all but totally unstoppable here. That's going to be huge for the already surging U.S. market.

But the stock I'm about to show you is set to soar (again) right now...

Best Small-Cap Stocks by Share Price Growth

Best Small Cap Stocks

The best small-cap stock has gained over 8,000% in per share price so far this year.

We compiled a list of the 10 best small-cap stocks, along with three stock picks to help you make mega profits in 2017.

Here are the 10 best small-cap stocks...

How to Make Nvidia Corp. Your Next Massive Profit Generator


Nvidia Corp. (Nasdaq: NVDA) is a giant in the rapidly expanding computer graphics processor segment. Over the past 12 months, it's boosted market share in a competitive niche by 39% and rewarded shareholders with 260% gains.

As a stock, it's remarkable, with a huge following on Wall Street. Nvidia is a consistent earnings-beater, and it's got a reputation for rallying back with gusto from any downturns, as it's recently begun to do. 

But Chris is looking at a special "buying vacuum" situation unfolding with Nvidia shares right now that's going to make some serious money.

Now, he's going to show you why he thinks people who buy the stock outright could see a fast 10% or 15% return as the stock slingshots back to where it "belongs," but he's also going to show you the cheapest way to play the stock for 50% or more...

Top 10 Most Expensive Stocks on U.S. Markets Now

Most Expensive Stocks

The most expensive stocks on the market today range in price from $700 to $300,000 a share.

We compiled a list of the stocks that are top dollar on the market today, along with three stocks to help you profit in 2017.

Here are the top 10 most expensive stocks available...

This “Rocky” Comeback Stock Is a Great Deal Right Now


Donald Trump's 140-character blasts were merely controversial before he won the election. But now, love him or hate him, @realDonaldTrump's social media "engagement" can seem downright earth-shaking sometimes, grabbing headlines, upending international relations, and knocking some of the world's savviest, most powerful CEOs on their heels.

Well, now it's under pressure once again, but Bill recommends getting in position now for a chance to make a killing on its hard-charging comeback. Check out his special video recommendation...